This is an observational study to evaluate TruGraf® testing in high immune risk kidney transplant recipients. TruGraf is the first and only non-invasive test approved by Medicare to rule out silent rejection in stable kidney transplant recipients.
Study Type
OBSERVATIONAL
Enrollment
19
5 mL collection PAXgene blood sample
Houston Methodist Research Institute
Houston, Texas, United States
Clinical Utility of TruGraf Results
Percent of total number of TruGraf results that the PI identified as having clinical utility
Time frame: 1 year
Correlation of TruGraf Results
Percent of total number of TruGraf results that the PI identified as being correlated to other clinical results obtained through the standard of care
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.